← Akebia Therapeutics, Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | ($135.7m) | ($76.9m) | ($143.6m) | ($279.7m) | ($383.5m) | ($282.8m) | — | ($51.9m) | ($69.4m) | ($5.3m) | — | |
| Depreciation, Depletion and Amortization | $296k | $617k | $899k | $2.2m | $2.1m | $1.9m | $1.7m | $1.6m | $1.5m | $1.3m | $1.6m | |
| Depreciation | $295k | $616k | $900k | $2.2m | $2.1m | $1.9m | $1.7m | $1.6m | $1.5m | $1.3m | $1.6m | |
| Amortization of Intangible Assets | — | — | $1.5m | $36.4m | $31.5m | $36.0m | — | $36.0m | $36.0m | $0 | — | |
| Deferred Income Tax Expense (Benefit) | $0 | $0 | ($28.5m) | ($6.6m) | $0 | $0 | — | $0 | $0 | $0 | ($33.2m) | |
| Share-based Payment Arrangement, Noncash Expense | $5.8m | $8.9m | $19.0m | $11.9m | $24.5m | $22.7m | — | $9.3m | $7.8m | $11.3m | $13.3m | |
| Share-based Payment Arrangement, Expense | $5.8m | $12.3m | $19.0m | $11.9m | $24.5m | $22.7m | — | $9.3m | $7.8m | $11.3m | $13.3m | |
| Goodwill, Impairment Loss | — | — | — | — | $0 | $0 | — | — | — | — | $8.1m | |
| Impairment of Intangible Assets (Excluding Goodwill) | — | — | — | — | $115.5m | $0 | — | — | — | — | — | |
| Other Nonoperating Income (Expense) | ($188k) | $204k | $81k | ($794k) | $1.9m | $2.4m | — | $887k | $94k | $58k | — | |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts Receivable | — | $393k | ($33.4m) | $22.2m | ($12.0m) | $24.0m | — | ($994k) | ($4.0m) | $14.1m | $18.6m | |
| Increase (Decrease) in Inventories | — | — | ($26k) | $29.1m | ($6.2m) | $25.8m | — | $2.5m | $28.4m | $23.1m | ($13.7m) | |
| Inventory Write-down | — | — | — | $7.1m | $20.1m | $15.6m | — | $1.6m | $4.2m | $2.5m | — | |
| Increase (Decrease) in Accounts Payable | ($274k) | $5.0m | $13.7m | $1.4m | $3.7m | ($11.7m) | — | ($5.2m) | ($1.4m) | $3.1m | ($3.6m) | |
| Net Cash Provided by (Used in) Operating Activities | $57.9m |
($56.2m)
-196.98%
|
($97.5m)
-73.60%
|
($257.4m)
-164.06%
|
($110.4m)
+57.12%
|
($253.0m)
-129.16%
|
($73.2m)
+71.08%
|
($23.4m)
+68.03%
|
($40.7m)
-73.88%
|
$68.0m
+267.22%
|
$41.6m
-38.89%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | $2.7m | $1.6m | $1.6m | $6.7m | $317k | $59k | $114k | $0 | $33k | $291k | ($12.1m) | |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property | ($306k) | — | $0 | ($2.1m) | $0 | $0 | — | $0 | $0 | ($172k) | ($4.7m) | |
| Gain (Loss) on Disposition of Property Plant Equipment | $306k | — | $0 | $2.1m | $0 | $0 | — | $0 | $0 | $172k | ($4.7m) | |
| Cash, Cash Equivalents, and Short-term Investments | $260.4m | $317.8m | $321.6m | $147.7m | $268.7m | $149.8m | — | — | — | — | — | |
| Debt Securities, Available-for-sale, Realized Gain (Loss) | — | — | $0 | $0 | $0 | $0 | — | — | — | — | — | |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale | $162.4m | $150.0m | $243.3m | $153.1m | $60.2m | $40.0m | — | — | — | — | — | |
| Net Cash Provided by (Used in) Investing Activities | $12.7m | ($177.3m) | $36.6m | $211.2m | ($40.0m) | $39.9m | ($114k) | $0 | ($33k) | ($7.9m) | ($12.1m) | |
| Cash flows from financing activities: | ||||||||||||
| Gain (Loss) on Extinguishment of Debt | — | — | — | — | $0 | $0 | $406k | $0 | ($517k) | $0 | — | |
| Proceeds from Issuance of Long-term Debt | — | — | — | $77.7m | $20.0m | $0 | — | $0 | $45.0m | $10.0m | $0 | |
| Proceeds from Issuance of Common Stock | $66.7m | $373.1m | $468.4m | $25.8m | $209.4m | $88.2m | $7.1m | $6.7m | $42.5m | $66.4m | $3.5m | |
| Net Cash Provided by (Used in) Financing Activities | $66.9m |
$116.2m
+73.63%
|
$96.6m
-16.93%
|
$89.0m
-7.86%
|
$231.7m
+160.45%
|
$133.7m
-42.29%
|
$14.6m
-89.08%
|
($25.2m)
-272.67%
|
$49.7m
+297.03%
|
$72.9m
+46.84%
|
($11.2m)
-115.36%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $137.6m | ($117.2m) | $35.7m | $42.7m | $81.3m | ($79.3m) | ($58.7m) | ($48.6m) | $9.0m | $133.0m | $157.3m | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $137.6m | ($117.2m) | $107.1m | $149.8m | $231.1m | $151.8m | ($58.7m) | $44.6m | $53.5m | $186.5m | $157.3m | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Proceeds from Stock Options Exercised | $124k | $1.3m | $647k | $560k | $1.2m | $0 | $67k | $1k | $385k | $1.7m | — | |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating Activities | — | — | — | $781k | $7.8m | $9.6m | $6.8m | $6.1m | $5.0m | $6.1m | — | |
| Additional Financial Items | ||||||||||||
| Gain (Loss) on Termination of Lease | — | — | — | — | — | — | — | ($524k) | $0 | $0 | — | |
| General and Administrative Expense | $22.2m | $27.0m | — | — | — | — | — | — | — | — | — | |
| Goodwill | — | — | $55.1m | $55.1m | $55.1m | $55.1m | $59.0m | $59.0m | $59.0m | $59.0m | $8.1m | |
| Income Tax Expense (Benefit) | — | — | ($28.3m) | ($6.6m) | $0 | $0 | — | — | — | $1.6m | — | |
| Investment Income, Interest | $901k | — | — | — | — | — | — | — | — | — | — | |
| Noncash Merger Related Costs | — | — | $13.4m | — | $0 | — | — | — | — | — | — | |
| Operating Expenses | $138.0m | $257.9m | $378.1m | $476.0m | $375.8m | $325.5m | — | $166.7m | $147.5m | $173.2m | — |